Development of a New Class of Broad-Stage Antimalarial Agents

新型多阶段抗疟药物的开发

• 批准号: nhmrc : 2000087
• 金额: $ 72.9万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-new-class-antimalarial-agents/1779504
• 关键词: Development; New; Class; Broad; Stage

In 2017, there were almost 220 million cases of malaria across 90 different countries, associated with 435,000 deaths, and with 65-70% of all malaria deaths tragically being children under the age of 5 years old. No significant progress in reducing global malaria cases has been made over the last 4 years and the need for new and better treatments remains dire. In this research and development plan, we will develop novel and safer drugs for the treatment of drug resistant malaria.

2017 年，90 个不同国家出现近 2.2 亿例疟疾病例，导致 435,000 人死亡，而所有疟疾死亡人数中 65-70% 是 5 岁以下儿童。过去四年来，在减少全球疟疾病例方面没有取得重大进展，仍然迫切需要新的、更好的治疗方法。在这项研发计划中，我们将开发新型且更安全的药物来治疗耐药性疟疾。